Price/Sales of Supernus Pharmaceuticals, Inc.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|Company||Industry||Return on equity|
|PX Praxair, Inc.||NYSE > Basic Industries > Major Chemicals||27.08%|
|MXIM Maxim Integrated Products, Inc.||NASDAQ > Technology > Semiconductors||27.17%|
|TPIC TPI Composites, Inc.||NASDAQ > Energy > Industrial Machinery/Components||27.18%|
|TSEM Tower Semiconductor Ltd.||NASDAQ > Technology > Semiconductors||27.19%|
|NMRK Newmark Group, Inc.||NASDAQ||27.19%|
|TEP Tallgrass Energy Partners, LP||NYSE > Public Utilities > Natural Gas Distribution||27.22%|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||27.27%|
|OPNT Opiant Pharmaceuticals, Inc.||NASDAQ > Basic Industries > Precious Metals||2,031.11%|
|PBT Permian Basin Royalty Trust||NYSE > Energy > Oil & Gas Production||4,888.60%|
|IDXX IDEXX Laboratories, Inc.||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||8,410.92%|
|NRT North European Oil Royality Trust||NYSE > Energy > Oil & Gas Production||8,437.44%|
|CQH Cheniere Energy Partners LP Holdings, LLC||NYSEMKT > Public Utilities > Oil/Gas Transmission||9,523.81%|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||9,929.09%|